BreezeMeds Offers Compounded GLP-1 Weight Loss Medications

Telehealth Platform Provides Semaglutide and Tirzepatide Options, but Regulatory Landscape Evolving

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

BreezeMeds is a telehealth platform that connects individuals with licensed healthcare providers and partner compounding pharmacies for access to prescription GLP-1 weight loss medications, including compounded semaglutide injections, oral semaglutide, and oral tirzepatide. The platform offers convenience, but the compounded nature of the medications means they have not been reviewed by the FDA for safety, effectiveness, or quality as finished products. The regulatory environment for compounded GLP-1 medications has shifted, with the FDA signaling increased enforcement attention in this area.

Why it matters

The availability and regulatory status of compounded GLP-1 weight loss medications is an important consideration for consumers, as the FDA has resolved drug shortages and is now taking a closer look at certain non-FDA-approved offerings in this category. Understanding the distinctions between branded, FDA-approved GLP-1 medications and compounded formulations is crucial when evaluating telehealth weight loss platforms.

The details

BreezeMeds offers compounded semaglutide injections starting at $199 per month, compounded oral semaglutide starting at $299 per month, and compounded oral tirzepatide starting at $399 per month. The platform uses a three-entity model, with BreezeMeds as the telehealth technology provider, independent licensed medical providers evaluating patients, and partner 503A compounding pharmacies fulfilling prescriptions. Compounded medications are not FDA-approved finished products, and the regulatory landscape has evolved, with the FDA resolving drug shortages and signaling increased enforcement attention in this area.

  • The semaglutide drug shortage was officially resolved in February 2025.
  • Tirzepatide was removed from the FDA drug shortage list in late 2024.

The players

BreezeMeds

A telehealth platform that connects consumers with licensed healthcare providers and partner compounding pharmacies for access to prescription GLP-1 weight loss medications.

Licensed Medical Providers

Independent healthcare professionals who review patient health information and determine whether a GLP-1 prescription is clinically appropriate.

Partner Compounding Pharmacies

503A pharmacies that fulfill prescriptions written by the medical providers and are primarily regulated by state boards of pharmacy.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The availability and regulatory status of compounded GLP-1 weight loss medications is an evolving landscape, with the FDA signaling increased enforcement attention in this area. Consumers evaluating telehealth platforms like BreezeMeds should carefully consider the distinctions between compounded and FDA-approved GLP-1 medications, as well as the current regulatory environment, before making any purchasing decisions.